Meeting
2021 Genitourinary Cancers Symposium
A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
Presenter
David Johnson Einstein, MD
Beth-Israel Deaconess Medcl Ctr
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session: Advanced Prostate Cancer
Track
Prostate Cancer - Advanced
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03414034
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr TPS186)
DOI
10.1200/JCO.2021.39.6_suppl.TPS186
Abstract #
TPS186
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Matching-adjusted indirect comparisons (MAICs) of talazoparib plus enzalutamide (TALA+ENZA) versus olaparib plus abiraterone and prednisone/prednisolone (OLAP+AAP) for first-line (1L) therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair mutations (HRRm)/BRCAm.
Speaker: Allison Thompson, PharmD
Videos & Slides
2017 ASCO Annual Meeting
A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).
Speaker: Kim N. Chi, MD
Videos & Slides
2016 ASCO Annual Meeting
Co-targeting androgen receptor (AR) and DNA repair: A randomized ETS gene fusion-stratified trial of abiraterone + prednisone (Abi) +/- the PARP1 inhibitor veliparib for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) (NCI9012)—A University of Chicago phase II consortium trial.
Speaker: Maha Hussain, MD, FACP, FASCO
Speaker: Panel Discussion